Target expression details
Target General Information | |||||
---|---|---|---|---|---|
Target ID | T91331 | ||||
Target Name | Fibroblast growth factor receptor 3 | ||||
Synonyms | FGFR-3; CD333; Fibroblast growth factor receptor 3; FGFR3 | ||||
Target Type | Clinical Trial | ||||
Gene Name | FGFR3 | ||||
Biochemical Class | Kinase | ||||
UniProt ID | FGFR3_HUMAN | ||||
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals | |||||
Disease | Liver cancer | ||||
Example drug | BMS-582664 | Phase 3 | [1], [2], [3] | ||
Tissue | Liver tissue | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.02 Z-score: 0.05 P-value: 8.57E-01 |
||||
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: -0.03 Z-score: -0.10 P-value: 2.53E-01 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of the persons with other diseases not directly affecting the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Alzheimer's disease | ||||
Example drug | MK-2461 | Phase 1/2 | [4], [3] | ||
Tissue | Entorhinal cortex | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.08 Z-score: 0.10 P-value: 5.83E-03 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Renal cancer | ||||
Example drug | Dovitinib | Phase 1/2 | [5], [6], [3] | ||
Tissue | Kidney | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: -0.99 Z-score: -2.34 P-value: 1.39E-06 |
||||
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section | Fold-change: -0.92 Z-score: -2.40 P-value: 1.83E-47 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Myeloma | ||||
Example drug | Anti-FGFR3 | Phase 1 | [7], [3] | ||
Tissue | Bone marrow | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 0.04 Z-score: 0.39 P-value: 6.39E-16 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Disease | Retinoblastoma tumor | ||||
Example drug | PD-0183812 | Terminated | [8], [3] | ||
Tissue | Uvea | ||||
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual | Fold-change: 1.46 Z-score: 8.79 P-value: 9.72E-06 |
||||
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
![]() |
|||||
Target Gene Expression Profiles in Other Tissues of Healthy Individuals | |||||
![]() |
|||||
Reference | |||||
REF 1 | ClinicalTrials.gov (NCT00908752) Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC. U.S. National Institutes of Health. | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8097). | ||||
REF 3 | NCBI GEO: archive for functional genomics data sets--update. | ||||
REF 4 | MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. | ||||
REF 5 | A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2008 Apr 1;14(7):2075-81. | ||||
REF 6 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5962). | ||||
REF 7 | Clinical pipeline report, company report or official report of Genentech (2011). | ||||
REF 8 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014130) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.